
BioGenCell have teamed up with Laniado Hospital to clinically develop its groundbreaking technology. The hospital is a Technion affiliated that is renowned for its compassionate care and leadership in cutting-edge medicine. Laniado Hospital has supported BioGenCell, a clinical phase company, since its inception.
Before establishing BioGenCell, its entrepreneurs Dr. Yael Porat and Prof. Michael Belkin developed successful stem cell therapies for blood vessels diseases in heart patients (more than 400 ‘no option’ heart patients were treated) that were also applied in 2 successful clinical studies to Critical limb ischemia patients. Both Dr. Porat (XTL, Teva, TheraVitae) and Prof. Belkin (Incumbent of the Chair of Ophthalmology in Tel Aviv University, and a member of the IRB of Sheba medical Center for more than 30 years) are highly experienced with product and clinical development in full compliance with the high standards required by different regulatory authorities.
Key scientific and business opinion leaders who share the company’s vision are advising the team to further enhance the extensive experience of the team’s founders.
For more data about BioGenCell and the groundbreaking proprietary technology, take a look at the web site here www.BioGenCell.Net